XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Acquisitions and Other Transactions (Narrative) (Details)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Nov. 07, 2022
USD ($)
Jun. 30, 2023
USD ($)
right
$ / shares
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
right
$ / shares
Jun. 30, 2023
USD ($)
right
$ / shares
Jun. 30, 2022
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Business Acquisition [Line Items]                  
Contingent consideration   $ 379.1   $ 379.1 $ 379.1     $ 375.0  
Goodwill   10,532.5   10,532.5 10,532.5     10,425.8  
Revenues   3,918.6 $ 4,116.8   7,647.7 $ 8,308.5      
Net earnings attributable to Viatris Inc. common shareholders   264.0 $ 313.9   488.7 713.1      
In Process Research And Development, Fair value Measurement Input, Discount Rate 23.90%                
Prepaid expenses and other current assets   1,725.1   1,725.1 1,725.1     1,811.2  
Famy Life Sciences                  
Business Acquisition [Line Items]                  
Equity Securities, FV-NI                 $ 25.0
Gain (Loss) on Disposition of Stock in Subsidiary or Equity Method Investee         18.9        
Mapi Pharma Ltd. | Variable Interest Entity, Not Primary Beneficiary                  
Business Acquisition [Line Items]                  
Variable Interest Entity, Maximum Milestone Payments   90.0   90.0 90.0        
Variable Interest Entity, Financial or Other Support, Amount   30.0              
Equity Securities, FV-NI, Unrealized Gain (Loss)   45.6              
Other Assets   132.1   132.1 132.1     56.4  
Gain (Loss) on Investments         62.1 $ 16.5      
Prepaid expenses and other current assets   $ 52.5   $ 52.5 $ 52.5     $ 42.5  
Product Rights And Licenses                  
Business Acquisition [Line Items]                  
Finite-lived intangible assets, estimated useful life, in years   10 years   10 years 10 years        
Oyster Point Pharma Acquisition                  
Business Acquisition [Line Items]                  
Business Combination, Consideration Transferred         $ 427.4        
Business Acquisition, Share Price | $ / shares   $ 11   $ 11 $ 11        
Business Acquisition, Non-Transferable Contingent Value Right, Number Of Rights | right   1   1 1        
Business Acquisition, Contingent Consideration Per Share | $ / shares   $ 2   $ 2 $ 2        
Contingent consideration   $ 60.0   $ 60.0 $ 60.0        
Business Combination, Acquisition Related Costs         19.8        
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory         29.3        
Business Acquisition, Provisional Information, Initial Accounting Incomplete, Adjustment, Amortization   7.3     14.7        
Goodwill   5.9   5.9 5.9        
Revenues       16.5          
Net earnings attributable to Viatris Inc. common shareholders       85.8          
Payments to Acquire Businesses, Net of Cash Acquired   392.7   392.7 392.7        
Oyster Point Pharma Acquisition | Product Rights And Licenses                  
Business Acquisition [Line Items]                  
Acquired intangible assets   $ 334.0   $ 334.0 $ 334.0        
Famy Life Sciences Acquisition                  
Business Acquisition [Line Items]                  
Business Combination, Consideration Transferred $ 281.0                
Goodwill 89.3                
Payments to Acquire Businesses, Net of Cash Acquired 325.0                
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value 43.9                
Famy Life Sciences Acquisition | In Process Research and Development                  
Business Acquisition [Line Items]                  
Acquired intangible assets $ 290.0                
Famy Life Sciences Acquisition | In Process Research and Development | Scenario, Forecast                  
Business Acquisition [Line Items]                  
Acquired intangible assets             $ 120.0    
Viatris Inc.                  
Business Acquisition [Line Items]                  
Subsidiary, Ownership Percentage, Noncontrolling Owner                 13.50%